Boehringer to work with Pfenex molecules; Alkermes releases Phase II results;

@FierceBiotech: GSK plots new approach to working with academia. Story | Follow @FierceBiotech

@JohnCFierce: BIO: Overall success rates from Phase I to FDA approval is nearly 9%. Item | Follow @JohnCFierce 

> Pfenex and Boehringer Ingelheim have reached an agreement that will give Boehringer non-exclusive access to Pfenex Expression Technology for work on the company's proprietary molecules. No financial details were disclosed. Pfenex release

> ALKS 37, Alkermes' peripherally restricted opioid antagonist performed well in a clinical trial testing its efficacy on opioid-induced bowel dysfunction, according to preliminary results. Alkermes says the the treatment was well tolerated and improved GI motility. Alkermes release

> Bridgewater, NJ-based NovaDel Pharma has entered an agreement to raise $1.6 million via 1,667 Series A Convertible Preferred stock. Roth Capital Partners served as the only placement agent. NovaDel release

And Finally... Potential heart treatments could be tested on human cells in a lab dish, rather than in mice, thanks to new stem cell technology. Report